Product news

Share this article:

Mylan Pharmaceuticals received final approval from the FDA for its Abbreviated New Drug Application for Doxycycline Tablets, 150 mg. Doxycycline Tablets are the generic version of Par Pharmaceutical's Doxycycline Tablets, 150 mg, marketed as Adoxa  Tablets by Doak Dermatologics. Doxycycline Tablets had US sales of approximately $34 million for the 12 months ending March 31, 2007 for the 150 mg. strength. In addition to this new product strength, Mylan previously received approval and is marketing the 50 mg, 75 mg and 100 mg strengths of Doxycycline Tablets.


 

King Pharmaceuticals announced plans to discontinue Florinef (fludrocortisone acetate tablets, USP), a drug used as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease for the treatment of salt losing adrenogenital syndrome.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.